Abstract

The potential of transgenic protein production in the milk of livestock has been clearly demonstrated. Complex therapeutic proteins, such as fibrinogen, can be obtained at higher yields than would be possible through mammalian cell culture. Purification has been shown to be reasonably simple and cost effective for a number of proteins. The issue of regulatory compliance has also been addressed and products derived from the milk of transgenic livestock, such as AAT, have entered clinical trials.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call